Robert Burr Livingston, M.D.
Affiliations: | 1946-1952 | Physiology | Yale University School of Medicine, New Haven, CT |
1952-1957 | Anatomy and Physiology | UCLA School of Medicine, Los Angeles, CA, United States | |
1956-1965 | National Institute of Neurological Diseases and Blindness | National Institute for Mental Health, North Bethesda, MD, United States | |
1965-1989 | Neurosciences | UCSD School of Medicine, San Diego, CA, United States |
Area:
neuroanatomy, neurophysiologyWebsite:
https://senate.universityofcalifornia.edu/_files/inmemoriam/html/RobertBurrLivingston.htmlGoogle:
"Robert Burr Livingston" OR "Robert B Livingston"Bio:
(1918 - 2002)
https://ucsdnews.ucsd.edu/archive/newsrel/health/RLInMemoriam.htm
https://library.ucsd.edu/speccoll/findingaids/mss0418.html#bioghist
Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Gralow JR, Barlow WE, Paterson AHG, et al. (2019) Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. Journal of the National Cancer Institute |
Segar JM, Reed D, Stopeck A, et al. (2019) A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer. The Oncologist |
Mehta RS, Barlow WE, Albain KS, et al. (2019) Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. The New England Journal of Medicine. 380: 1226-1234 |
Mehta R, Barlow W, Albain K, et al. (2018) Abstract PD5-07: A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226 Cancer Research. 78 |
Potkul RK, Unger JM, Livingston RB, et al. (2016) Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. Npj Breast Cancer. 2: 16024 |
Woodward WA, Barlow WE, Jagsi R, et al. (2016) The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814. International Journal of Radiation Oncology, Biology, Physics. 96: S146 |
Nahleh ZA, Barlow WE, Hayes DF, et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Research and Treatment |
Albain KS, Unger JM, Livingston RB, et al. (2016) Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. Journal of Clinical Oncology. 34: 547-547 |
Chalasani P, Nagy D, Livingston R, et al. (2016) Abstract P4-07-07: Evaluating Rad51/geminin protein expression as an indicator of homologous recombination deficiency in breast cancer models Cancer Research. 76 |
Zirpoli GR, McCann SE, Sucheston-Campbell LE, et al. (2016) Abstract 3413: Supplement use and chemotherapy-induced peripheral neuropathy in breast cancer patients treated on SWOG study S0221 Cancer Research. 76: 3413-3413 |